HUTCHMED (China) Ltd
HKEX:13
HUTCHMED (China) Ltd
Tax Provision
HUTCHMED (China) Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Tax Provision
-$4.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Tax Provision
-HK$386.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-30%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Tax Provision
-¥631.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Tax Provision
-¥492.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-3%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Tax Provision
-¥142.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-7%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Tax Provision
-HK$2.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
HUTCHMED (China) Ltd
Glance View
HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.
See Also
What is HUTCHMED (China) Ltd's Tax Provision?
Tax Provision
-4.7m
USD
Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Tax Provision amounts to -4.7m USD.
What is HUTCHMED (China) Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-14%
Over the last year, the Tax Provision growth was 30%.
You don't have any saved screeners yet